FORMYCON AG |
Market Closed -
Other stock markets
|
After market 11:59:26 pm | |||
| 41 EUR | +0.12% |
|
41.22 | +0.55% |
| 25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FORMYCON AG | Other Biotechnology & Medical Research | +0.12% | +4.86% | -27.30% | -41.09% | +12.64% | 772M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- FYB Stock
- Charts Formycon AG
- Comparison Chart
